Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
inezetamab (AMG994)
i
Other names:
AMG 994, AMG994, AMG-994
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Amgen, BeiGene
Drug class:
Mesothelin inhibitor, CD40 agonist
Related drugs:
‹
TC-210 (7)
CT-95 (1)
HK013 (1)
ABBV-428 (0)
AMG 305 (0)
CRS-207 (0)
CT-1119 (0)
FH-TCR-Tᴍsʟɴ (0)
GrB-Fc-SD1 (0)
HPN536 (0)
LMB-100 (0)
NI-1801 (0)
NM28-2746 (0)
dsFv (0)
SZ011 (0)
TC-510 (0)
MORAb-009 (0)
anti-Mesothelin CAR NK Cells (0)
autologous redirected RNA meso-CIR T cells (0)
cam1615SS1 (0)
JNJ-64041757 (0)
BAY 2287411 (0)
ex-vivo autologous dendritic cells vaccine (4)
ATOR-4066 (0)
CDX-1140 (0)
CP-870893 (0)
Chi Lob 7/4 (0)
GEN1042 (0)
GM.CD40L cell vaccine (0)
ISF35 (0)
MEDI5083 (0)
MP0317 (0)
NG-350A (0)
SHR-7367 (0)
SL-172154 (0)
YH003 (0)
SEA-CD40 (0)
LVGN7409 (0)
ABBV-927 (0)
ADC-1013 (0)
RG7876 (0)
PYX-107 (0)
TC-210 (7)
CT-95 (1)
HK013 (1)
ABBV-428 (0)
AMG 305 (0)
CRS-207 (0)
CT-1119 (0)
FH-TCR-Tᴍsʟɴ (0)
GrB-Fc-SD1 (0)
HPN536 (0)
LMB-100 (0)
NI-1801 (0)
NM28-2746 (0)
dsFv (0)
SZ011 (0)
TC-510 (0)
MORAb-009 (0)
anti-Mesothelin CAR NK Cells (0)
autologous redirected RNA meso-CIR T cells (0)
cam1615SS1 (0)
JNJ-64041757 (0)
BAY 2287411 (0)
ex-vivo autologous dendritic cells vaccine (4)
ATOR-4066 (0)
CDX-1140 (0)
CP-870893 (0)
Chi Lob 7/4 (0)
GEN1042 (0)
GM.CD40L cell vaccine (0)
ISF35 (0)
MEDI5083 (0)
MP0317 (0)
NG-350A (0)
SHR-7367 (0)
SL-172154 (0)
YH003 (0)
SEA-CD40 (0)
LVGN7409 (0)
ABBV-927 (0)
ADC-1013 (0)
RG7876 (0)
PYX-107 (0)
›
Associations
News
Trials
Filter by
Latest
1year
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=11, Completed, Amgen | Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Jun 2023
1 year ago
Trial completion • Trial completion date • Combination therapy • Metastases
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)
over1year
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Amgen | Trial completion date: Aug 2024 --> Sep 2023 | Trial primary completion date: Feb 2024 --> Jun 2023
over 1 year ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)
2years
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Amgen | Trial completion date: Mar 2023 --> Aug 2024 | Trial primary completion date: Jan 2023 --> Feb 2024
2 years ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)
over2years
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=214 --> 11 | Trial completion date: Aug 2025 --> Mar 2023 | Trial primary completion date: Feb 2025 --> Jan 2023
over 2 years ago
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)
over2years
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=214, Recruiting, Amgen | Trial primary completion date: Aug 2025 --> Feb 2025
over 2 years ago
Trial primary completion date • Combination therapy
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)
almost3years
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=214, Recruiting, Amgen | Trial completion date: Oct 2024 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Aug 2025
almost 3 years ago
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login